Neuroprotection with Angiotensin Receptor Antagonists: A Review of the Evidence and Potential Mechanisms
The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.
Abstract
The peptide hormone angiotensin (A)-II, the major effector peptide of the renin-angiotensin system (RAS), is well established to play a pivotal role in the systemic regulation of blood pressure, fluid, and electrolyte homeostasis. Recent biochemical and neurophysiologic studies have documented local intrinsic angiotensin-generating systems in organs and tissues such as the brain, retina, bone marrow, liver, and pancreas. The locally generated angiotensin peptides have multiple and novel actions including stimulating cell growth and anti-proliferative and/or antiapoptotic actions. In the mammalian brain, all components of the RAS are present including angiotensin receptor subtypes 1 (AT(1)) and 2 (AT(2)). A-II exerts most of its well defined physiologic and pathophysiologic actions, including those on the central and peripheral nervous system, through its AT(1) receptor subtype. While the AT(1) receptor is responsible for the classical effects of A-II, it has been found that the AT(2) receptor is linked to totally different signalling mechanisms and this has revealed hitherto unknown functions of A-II. AT(2) receptors are expressed at low density in many healthy adult tissues, but are upregulated in a variety of human diseases. This receptor not only contributes to stroke-related pathologic mechanisms (e.g. hypertension, atherothrombosis, and cardiac hypertrophy) but may also be involved in post-ischemic damage to the brain. It has been reported that the AT(2) receptor regulates several functions of nerve cells, e.g. ionic fluxes, cell differentiation, and neuronal tissue regeneration, and also modulates programmed cell death. In this article, we review the experimental evidence supporting the notion that blockade of brain AT(1) receptors can be beneficial with respect to stroke incidence and outcome. We further delineate how AT(2) receptors could be involved in neuronal regeneration following brain injury such as stroke or CNS trauma. The current review is focussed on some of the new functions arising from the locally formed A-II with particular attention to its emerging neuroprotective role in the brain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ARBs may be superior to ACEIs188, because of their selective binding with the angiotensin receptor type I, since activation of angiotensin type II receptor has protective effects, leading to vasodilation, neuronal differentiation, and axonal regeneration189.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [189]
Citations
Cites
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Self-citationHansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
Stoll, M., Steckelings, U. M., Paul, M., Bottari, S. P., Metzger, R., & Unger, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117710 · Cited by 906
Self-citationREGULATION OF CERAMIDE PRODUCTION AND APOPTOSIS
Kolesnick, R. N., & Krönke, M. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.643 · Cited by 803
Tigerstedt, R., & Bergman, P. Q. (1898) · Skandinavisches Archiv Für Physiologie · doi:10.1111/j.1748-1716.1898.tb00272.x · Cited by 794
Angiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
Singh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Angiotensin II type 2 receptor mediates programmed cell death.
Yamada, T., Horiuchi, M., & Dzau, V. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.156 · Cited by 697
BCL-2 GENE FAMILY IN THE NERVOUS SYSTEM
Merry, D. E., & Korsmeyer, S. J. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.245 · Cited by 588
Research works printed but not linked: 6
- Dzau, 1994, J Hypertens Suppl, 12, S3
- Unger, 1996, J Hypertens Suppl, 14, S95
- Timmermans, 1993, Pharmacol Rev, 45, 205
- Stier, 1993, J Hypertens Suppl, 11, S37
- Balla, 1991, Mol Pharmacol, 40, 401
- Bertolino, 1994, J Pharmacol Exp Ther, 268, 747
Cited by
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Roles of vascular risk factors in the pathogenesis of dementia
Takeda, S., Rakugi, H., & Morishita, R. (2019) · Hypertension Research · doi:10.1038/s41440-019-0357-9 · Cited by 100
Wang, W., Ma, X., Han, J., Zhou, M., Ren, H., Pan, Q., Zheng, C., & Zheng, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146197 · Cited by 75
Ishrat, T., Pillai, B. A., Soliman, S. M., Fouda, A. Y., Kozak, A., Johnson, M. H., Ergul, A., & Fagan, S. C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8830-6 · Cited by 70
Metadata
- Authors
- Wilms, H., Rosenstiel, P., Unger, T., Deuschl, G., & Lucius, R.
- Affiliations
- Christian-Albrechts-Universität zu Kiel (DE)
- Humboldt-Universität zu Berlin (DE)
- Corresponding author
- Lucius, Ralph
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2005
- Volume
- 5
- Issue
- 4
- Pages
- 245-253
- ISSN
- 1175-3277 (ISSN-L)
- OpenAlex
- W45749536
- Cited by
- 52
- References
- 102
- Citations by year
- 2024: 2 · 2022: 3 · 2021: 5 · 2019: 4 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 6
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Keywords
- angiotensin II, angiotensin receptor blockers, renin-angiotensin system, angiotensin II type 1 receptor, angiotensin II type 2 receptor, neuroprotection, stroke, brain injury, neuronal regeneration, apoptosis, cell proliferation, CNS trauma
- MeSH terms
- Animals, Brain Chemistry, Humans, Nerve Regeneration, Signal Transduction, Apoptosis, Neuroprotective Agents, Stroke, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection with Angiotensin Receptor Antagonists: A Review of the Evidence and Potential Mechanisms. https://app.cochat.ai/papers/10.2165/00129784-200505040-00004
- The paper
- Wilms, H., Rosenstiel, P., Unger, T., Deuschl, G., & Lucius, R. (2005). Neuroprotection with Angiotensin Receptor Antagonists: A Review of the Evidence and Potential Mechanisms. American Journal of Cardiovascular Drugs. https://doi.org/10.2165/00129784-200505040-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.